BEAMJPM2025Presenation_vF

PRECISION GENETIC MEDICINES THROUGH BASE EDITING2025 J.P. Morgan Healthcare ConferenceNASDAQ: BEAMCautionary note regarding forward-looking statementsThis presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding: the initiation, timing, progress and results of preclinical studies and research and development programs, including the initiation, design and progress of clinical trials, including trials for BEAM-101, BEAM-103, BEAM-301 and BEAM-302; the advancement of our pipeline and additional liver programs in multiple preclinical studies; our current expectations and anticipated results of operations, including our expecteduse of capital; our estimated cash, cash equivalents and marketable securities as of December 31, 2024 and our expectations related thereto; the sufficiency of our capital resources to fund operating expenses and capital expenditure require